Prescribing Controlled Substances by Telehealth: The DEA Rules

Yes — with a date on it.

The federal telemedicine rule at 21 CFR 1307.41 is written around a prior in-person medical evaluation, and that is exactly the requirement the Drug Enforcement Administration and HHS telemedicine flexibilities suspend.

The current rule authorizes "all DEA-registered practitioners" to "remotely prescribe Schedules II–V controlled substances … without an in-person medical evaluation" — flexibilities that have been in place, in some form, since March 2020.

Psychiatric nurse practitioners are inside that coverage.

The DEA registers NPs as "mid-level practitioners" under 21 CFR 1300.01, so a PMHNP with an active registration operates under the same flexibilities as any other DEA registrant.

The one in force now is the fourth temporary extension, effective January 1, 2026 through December 31, 2026.

The series matters because each rule carries its own end date — DEA and HHS have renewed the flexibilities four times:

Every one of these is a temporary rule with an expiration date.

None of them changed the underlying requirement permanently — which is why the question "can a PMHNP prescribe controlled substances by telehealth?" carries a date in its answer.

The permanent replacement exists only as a proposal.

The "Special Registrations for Telemedicine and Limited State Telemedicine Registrations" rulemaking, published January 17, 2025 with comments closing March 18, 2025, "would establish a Special Registration framework and authorize three types of Special Registration" — a new registration layer built specifically for telemedicine prescribing.

As of September 24, 2026 it is still only a proposal: a search of DEA documents in the Federal Register found no final rule.

DEA's own stated reason for the fourth extension was to "thoroughly consider … the comments made to the Special Registration for Telemedicine NPRM."

From here, one of three things happens.

DEA and HHS issue a fifth extension, and the current window moves again.

They finalize the special-registration rule, and telemedicine prescribing gains its own registration framework.

Or neither lands by December 31, 2026 — and the prior in-person-evaluation requirement comes back into force.

One telemedicine route is codified as a final rule rather than a temporary extension.

Since December 31, 2025, DEA has allowed practitioners to prescribe Schedule III–V FDA-approved medications for opioid use disorder via telemedicine, including audio-only.

After reviewing the state prescription drug monitoring program (PDMP), the practitioner "may prescribe an initial six-month supply of such medications (split amongst several prescriptions totaling six calendar months) through audio-only means."

That rule matters disproportionately to PMHNPs, who carry much of the medication-assisted treatment workload.

Two related changes simplified the paperwork around it.

The separate "X-waiver" is gone: the Restoring Hope for Mental Health and Well-Being Act of 2022 removed the statutory provisions behind it, and DEA's final rule implementing the removal took effect July 9, 2026.

And since June 27, 2023, every DEA registrant affirms a one-time eight-hour training on treating substance use disorders at registration; graduates of an advanced practice nursing program within five years of that date whose curriculum included the eight hours are deemed to have met it.

The registration mechanics are in how to become a psychiatric nurse practitioner.

Telehealth collapses the distance between clinician and patient.

It does not collapse the licensure map.

The working rule is that you must generally be licensed where the patient is located — and for PMHNPs there is no multistate shortcut.

The APRN Compact is not in effect anywhere: five states have enacted it and seven are needed.

The Nurse Licensure Compact's 43 jurisdictions move an RN licence only, with no nurse practitioner authority attached.

The same patient-location principle, and how few compacts are actually issuing privileges, is documented on the therapy side in telehealth across state lines.

State prescribing limits bind through a video visit exactly as they bind in an exam room.

The clearest example: five states — Alabama, Georgia, Missouri, Oklahoma, and Texas — bar NPs from prescribing Schedule II stimulants in ordinary outpatient practice, and no federal window makes telehealth ADHD prescribing lawful there.

The state-by-state map of practice authority, transition rules, and exits is in full, reduced and restricted practice.

States also write telemedicine-specific controlled-substance rules of their own.

New Hampshire's nurse practice act, for example, lets APRNs prescribe Schedule II–IV controlled drugs by telemedicine, provided a subsequent evaluation happens at intervals no longer than a year (RSA 326-B:11).

Several states separately restrict telehealth practice or Schedule II prescribing by NPs.

The federal flexibilities lift none of it.

Yes.

The flexibilities cover "all DEA-registered practitioners," so the federal window and the December 31, 2026 date are identical for a psychiatrist and a PMHNP — as is the buprenorphine rule and the proposed special registration.

Where the two diverge is the state layer beneath.

A psychiatrist holds a separate licence from each state medical board where patients sit, and the Interstate Medical Licensure Compact expedites those applications without replacing them: 44 states plus DC and Guam have joined, and 40 jurisdictions can currently act as a home state, per the commission's June 26, 2026 announcement.

What the IMLC does and does not do is covered in what a psychiatrist does.

The answer to the opening question has three layers — federal window, state licence, state drug limits — and each one moves on its own clock.

Before relying on any summary, including this one:

Employers scope telehealth prescribing differently in every posting — browsing open psychiatric nurse practitioner roles shows how the same licence lands in remote-first, hybrid, and in-person practice.

This article is general career information, not legal, clinical, or medical advice, and it is not guidance for anyone seeking treatment. Controlled-substance schedules, telemedicine rules, and licensure are set by the DEA, state legislatures, boards of nursing, and state medical boards, and all of them change — confirm the current rules with the patient's state board and the DEA before relying on any of it.